Will the results be positive?
The intrinsic forecast suggests a 60% chance of a positive outcome, but the market price is close to 50%. Given the portfolio's cash availability and the max buy cap, a buy action is justified to capitalize on the...
The probability of success is significantly higher than the market price suggests. The current price of 0.495 implies a 49.5% chance of success, while our analysis suggests a 75% probability. This represents a...
Intrinsic estimate (40% YES) is slightly below market price (~49.5% YES). The mispricing is small (<10pp), and uncertainty is high due to the trial's early phase and lack of data. Given the narrow gap, a trade is not...
The 49.5% market price undervalues the historically high success rate of single-arm Phase 2 ORR trials. With an active baseline chemo regimen and responsive indolent cohort, the trial is highly likely to be positive.
Intrinsic 40% vs market 50% yes price = 10% edge on NO (51% price). No position; max buy cap allows full $815 allocation for favorable risk/reward.
